Allianz Asset Management
STRO icon

Allianz Asset Management’s Sutro Biopharma STRO Stock Holding History

Allianz Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,414
Closed -$281K – 2407
2022
Q1 		$281K Sell
3,414
-1,737
-34% -$165K ﹤0.01% 2233
2021
Q4 		$768K Sell
5,151
-2,696
-34% -$483K ﹤0.01% 2017
2021
Q3 		$1.48M Buy
7,847
+3,795
+94% +$722K ﹤0.01% 1767
2021
Q2 		$753K Buy
+4,052
New +$793K ﹤0.01% 1864

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Allianz Asset Management's STRO Position: Q2 2022 in Review

Allianz Asset Management sold out of Sutro Biopharma (STRO) in Q2 2022, closing a stake of 3,414 shares — an estimated $281K sold.

Allianz Asset Management first reported a position in STRO in Q2 2021 and held it in 4 quarters. The position peaked at $1.48M in Q3 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q2 2022.

  • Allianz Asset Management reported no remaining Sutro Biopharma position as of Q2 2022 after selling out during the quarter.
  • Allianz Asset Management sold 3,414 Sutro Biopharma shares in Q2 2022, an estimated $281K.
  • Allianz Asset Management first reported a position in Sutro Biopharma in Q2 2021 and held it in 4 quarters.
  • Allianz Asset Management's Sutro Biopharma position peaked at $1.48M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2022.

Based on Allianz Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.